New York S 5013: Grants private citizens broad authorization to commence civil judicial actions under certain titles of the environmental conservation law

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S05013 Summary:

BILL NOS05013 

&nbsp

SAME ASNo Same As

&nbsp

SPONSORHARCKHAM

&nbsp

COSPNSR

&nbsp

MLTSPNSR

&nbsp

Amd §§3216, 3221 & 4303, Ins L

&nbsp

Requires health insurers to provide coverage for opioid antagonists and devices.

Go to top S05013 Actions:

BILL NOS05013 

&nbsp

02/18/2025REFERRED TO INSURANCE

01/07/2026REFERRED TO INSURANCE

Go to topS05013 Committee&nbspVotes:

Go to topS05013 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS05013 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 5013

 2025-2026 Regular Sessions

 IN SENATE

 February 18, 2025
 ___________

 Introduced by Sen. HARCKHAM -- read twice and ordered printed, and when
 printed to be committed to the Committee on Insurance

 AN ACT to amend the insurance law, in relation to requiring health
 insurers to provide coverage for opioid antagonists and devices

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Subsection (i) of section 3216 of the insurance law is
 2 amended by adding a new paragraph 41 to read as follows:
 3 (41) (A) (i) Every policy which provides coverage for prescription
 4 drugs shall include coverage for at least one opioid antagonist and
 5 device. Prior authorization may be required for non-generic forms of
 6 opioid antagonists and devices.
 7 (ii) As used in this paragraph "opioid antagonist and device" means a
 8 drug approved by the food and drug administration that, when adminis-
 9 tered, negates or neutralizes in whole or in part the pharmacological
 10 effects of an opioid in the body. "Opioid antagonist" shall be limited
 11 to naloxone and other medications approved by the department of health
 12 for such purpose.
 13 (B) The coverage mandated by this paragraph shall include opioid
 14 antagonists prescribed or dispensed via standing order or collaborative
 15 practice agreement intended for use on patients other than the insured.
 16 (C) Coverage provided under this paragraph may be subject to annual
 17 deductibles and co-insurance as deemed appropriate by the superintendent
 18 and that are consistent with those imposed on other benefits within a
 19 given policy.
 20 § 2. Subsection (l) of section 3221 of the insurance law is amended by
 21 adding a new paragraph 7-c to read as follows:
 22 (7-c) (A) (i) Every policy which provides coverage for prescription
 23 drugs shall include coverage for at least one opioid antagonist and
 24 device. Prior authorization may be required for non-generic forms of
 25 opioid antagonists and devices.

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD09743-02-5

 S. 5013 2

 1 (ii) As used in this paragraph "opioid antagonist and device" means a
 2 drug approved by the food and drug administration that, when adminis-
 3 tered, negates or neutralizes in whole or in part the pharmacological
 4 effects of an opioid in the body. "Opioid antagonist" shall be limited
 5 to naloxone and other medications approved by the department of health
 6 for such purpose.
 7 (B) The coverage mandated by this paragraph shall include opioid
 8 antagonists prescribed or dispensed via standing order or collaborative
 9 practice agreement intended for use on patients other than the insured.
 10 (C) Coverage provided under this paragraph may be subject to annual
 11 deductibles and co-insurance as deemed appropriate by the superintendent
 12 and that are consistent with those imposed on other benefits within a
 13 given policy.
 14 § 3. Section 4303 of the insurance law is amended by adding a new
 15 subsection (ww) to read as follows:
 16 (ww) (1) (A) Every policy which provides coverage for prescription
 17 drugs shall include coverage for at least one opioid antagonist and
 18 device. Prior authorization may be required for non-generic forms of
 19 opioid antagonists and devices.
 20 (B) As used in this subsection "opioid antagonist and device" means a
 21 drug approved by the food and drug administration that, when adminis-
 22 tered, negates or neutralizes in whole or in part the pharmacological
 23 effects of an opioid in the body. "Opioid antagonist" shall be limited
 24 to naloxone and other me